Medicus Pharma Ltd. (MDCXW)
| Market Cap | 9.63M -83.4% |
| Revenue (ttm) | n/a |
| Net Income | -56.66M |
| EPS | -1.66 |
| Shares Out | 63.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 0.1985 - 1.4500 |
| Beta | -0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About MDCXW
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was inco... [Read more]
News
Medicus to focus future clinical development of SkinJect on Gorlin syndrome
Medicus Pharma (MDCX) announced that it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and c...
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
Medicus Pharma price target raised to $1 from 90c at Alliance Global
Alliance Global analyst Matthew Venezia raised the firm’s price target on Medicus Pharma (MDCX) to $1 from 90c and keeps a Buy rating on the shares following a transfer of…
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussi...
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncolo...
Medicus Pharma price target lowered to 90c from $1 at Alliance Global
Alliance Global analyst Scott Henry lowered the firm’s price target on Medicus Pharma (MDCX) to 90c from $1 and keeps a Buy rating on the shares post tithe Q2 report.
Medicus Pharma reports Q2 EPS (21c) vs (43c) last year
“The second quarter of 2026 marked a defining period for Medicus as we successfully advanced both of our lead therapeutic platforms into their next stages of clinical and regulatory development,…
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Ex...
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operat...
Medicus Pharma Teverelix granted investigational new drug authorization in UAE
Medicus Pharma (MDCX) announced that the United Arab Emirates, or UAE, Department of Health – Abu Dhabi has granted investigational new drug authorization for the company’s PRECISION-E2 Phase 2a clini...
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health Randomized Phase 2a PRECISION-E2 study designed to evaluate a...
Medicus Pharma initiated with a Buy at Alliance Global
Alliance Global initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $1 price target Medicus is a life sciences company focused on the clinical development of novel therapeutic…
Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study
Medicus Pharma (MDCX) announced the FDA has completed its safety review of the company’s Investigational New Drug application for SKNJCT-005 and issued a “Study May Proceed” letter authorizing the ini...
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended pati...
Medicus Pharma receives FDA feedback, IRB approval for Teverelix study
Medicus Pharma (MDCX) announced that it has received written feedback from the FDA and central Institutional Review Board, or IRB, approval, with modifications, for its optimized Phase 2 clinical stud...
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-r...
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the ...
Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA
Medicus Pharma (MDCX) announced the submission of a Rare Pediatric Disease Designation request to the FDA for SkinJect, the company’s investigational doxorubicin-containing microneedle array patch, fo...
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs ...
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine...
Medicus Pharma submits substantial modification application through EU CTIS
Medicus Pharma (MDCX) announced the submission of a substantial modification application through the European Union Clinical Trials Information System, or CTIS, supporting the planned Phase 2b study o...
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity European regulatory filing s...
Medicus Pharma submits Protocol SKNJCT-005 to the FDA
Medicus Pharma (MDCX) announced the submission of Protocol SKNJCT-005 to the FDA under the company’s existing investigational new drug, or IND, application, for SkinJect into registrational developmen...
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs ...
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years Financing Provides Immediate Growth Capital t...